ANGLO-SWEDISH drugmaker AstraZeneca on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer and rare diseases.
Sales in the company's top business, oncology, grew 19 percent at constant currency rates to $5.33 billion and accounted for 41 percent of the total, while other divisions, such as rare diseases and respiratory and immunology, also raked in double-digit growth.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.